Agree Realty

With just a month left to the year, the S&P 500 is up 26% in 2024. Unless there's some major news over the next few weeks, the year will close out with a strong gain.» Mehr auf fool.com

Agree Realty is one of the more impressive triple-net lease REITs out there, with an upside that's non-trivial at the right valuation. That upside is no longer there, with the company trading far higher than when I bought it. As a result of this, using Q3'24 results, I am reiterating "Hold" on Agree Realty stock with the following specifics.» Mehr auf seekingalpha.com

Vancouver, British Columbia--(Newsfile Corp. - November 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce its plan to license its proprietary Accum® technology to pharma and biotech companies developing Antibody Drug Conjugates ("ADCs") to amplifying their ADC potency and potentially reducing the dosing. Defence operates on an innovative business model centered around its proprietary Accum® technology, a platform designed to significantly enhance the delivery and efficacy of biologics, including ADCs, radiopharmaceuticals, vaccines, and protein therapeutics.» Mehr auf newsfilecorp.com